Unknown

Dataset Information

0

Discontinuation of antiviral prophylaxis correlates with high prevalence of hepatitis B virus (HBV) reactivation in rheumatoid arthritis patients with HBV carrier state: a real-world clinical practice.


ABSTRACT: BACKGROUND: To investigate the risk of hepatitis B virus (HBV) reactivation in rheumatoid arthritis (RA) patients with HBV carrier state during treatment of disease-modifying antirheumatic drugs (DMARDs) and the use of antiviral prophylaxis in real-world clinical practice. METHODS: Consecutive RA patients with HBV carrier state were included. Clinical data including liver evaluation, HBV infection evaluation and the use of antiviral prophylaxis were recorded. RESULTS: Fifty-three RA patients with HBV carrier state were screened and 36 patients were qualified for analysis. Thirty-six percentage of patients developed HBV reactivation and 17% developed HBV hepatitis together with reactivation, one of which developed decompensate cirrhosis. Only 50% of patients accepted lamivudine although all patients were recommended antiviral prophylaxis with entecavir or tenofovir and only 31% continued during DMARDs therapy. Seventy-one percentage of patients who discontinued antiviral prophylaxis developed HBV reactivation 3?~?21 months after discontinuation. Logistic regression analyses showed discontinuation of antiviral prophylaxis (OR: 66, p?=?0.027), leflunomide (OR: 64, p?=?0.011) and past history of hepatitis (OR: 56, p?=?0.013) were risk factors of HBV reactivation. Past history of hepatitis (OR: 10, p?=?0.021) was also risk factor of HBV hepatitis together with reactivation. CONCLUSION: Our results suggest poor patient acceptance and discontinuation of antiviral prophylaxis should not be ignored for Chinese RA patients with HBV carrier state in real-world clinical practice. Discontinuation of antiviral prophylaxis, past history of hepatitis and LEF might increase risk of HBV reactivation for RA patients with HBV carrier state during DMARDs therapy.

SUBMITTER: Mo YQ 

PROVIDER: S-EPMC4320507 | biostudies-other | 2014

REPOSITORIES: biostudies-other

altmetric image

Publications

Discontinuation of antiviral prophylaxis correlates with high prevalence of hepatitis B virus (HBV) reactivation in rheumatoid arthritis patients with HBV carrier state: a real-world clinical practice.

Mo Ying-Qian YQ   Liang An-Qi AQ   Ma Jian-Da JD   Chen Le-Feng LF   Zheng Dong-Hui DH   Schumacher H Ralph HR   Dai Lie L  

BMC musculoskeletal disorders 20141222


<h4>Background</h4>To investigate the risk of hepatitis B virus (HBV) reactivation in rheumatoid arthritis (RA) patients with HBV carrier state during treatment of disease-modifying antirheumatic drugs (DMARDs) and the use of antiviral prophylaxis in real-world clinical practice.<h4>Methods</h4>Consecutive RA patients with HBV carrier state were included. Clinical data including liver evaluation, HBV infection evaluation and the use of antiviral prophylaxis were recorded.<h4>Results</h4>Fifty-th  ...[more]

Similar Datasets

| S-EPMC4717401 | biostudies-literature
| S-EPMC7946964 | biostudies-literature
| S-EPMC7244777 | biostudies-literature